Matthew P. Young - Net Worth and Insider Trading
Matthew P. Young Net Worth
The estimated net worth of Matthew P. Young is at least $4 Million dollars as of 2025-05-07. Matthew P. Young is the EVP & CFO of Jazz Pharmaceuticals PLC and owns about 36,200 shares of Jazz Pharmaceuticals PLC (JAZZ) stock worth over $4 Million. Matthew P. Young is also the Director of PRA Health Sciences Inc and owns about 2,810 shares of PRA Health Sciences Inc (PRAH) stock worth over $464,240. Details can be seen in Matthew P. Young's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew P. Young has not made any transactions after 2019-03-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Matthew P. Young
Matthew P. Young Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matthew P. Young owns 3 companies in total, including CytomX Therapeutics Inc (CTMX) , PRA Health Sciences Inc (PRAH) , and Jazz Pharmaceuticals PLC (JAZZ) .
Click here to see the complete history of Matthew P. Young’s form 4 insider trades.
Insider Ownership Summary of Matthew P. Young
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| CTMX | CytomX Therapeutics Inc | 2018-06-13 | director |
| PRAH | PRA Health Sciences Inc | 2020-05-18 | director |
| JAZZ | Jazz Pharmaceuticals PLC | 2019-03-06 | SVP & CFO |
Matthew P. Young Latest Holdings Summary
Matthew P. Young currently owns a total of 2 stocks. Among these stocks, Matthew P. Young owns 36,200 shares of Jazz Pharmaceuticals PLC (JAZZ) as of March 6, 2019, with a value of $4 Million and a weighting of 89.66%. Matthew P. Young also owns 2,810 shares of PRA Health Sciences Inc (PRAH) as of November 16, 2017, with a value of $464,240 and a weighting of 10.34%.
Latest Holdings of Matthew P. Young
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals PLC | 2019-03-06 | 36,200 | 111.17 | 4,024,354 |
| PRAH | PRA Health Sciences Inc | 2017-11-16 | 2,810 | 165.21 | 464,240 |
Holding Weightings of Matthew P. Young
Matthew P. Young Form 4 Trading Tracker
According to the SEC Form 4 filings, Matthew P. Young has made a total of 0 transactions in Jazz Pharmaceuticals PLC (JAZZ) over the past 5 years. The most-recent trade in Jazz Pharmaceuticals PLC is the sale of 1,152 shares on March 6, 2019, which brought Matthew P. Young around $155,992.
According to the SEC Form 4 filings, Matthew P. Young has made a total of 0 transactions in PRA Health Sciences Inc (PRAH) over the past 5 years. The most-recent trade in PRA Health Sciences Inc is the sale of 5,115 shares on November 16, 2017, which brought Matthew P. Young around $408,688.
Insider Trading History of Matthew P. Young
- 1
Matthew P. Young Trading Performance
Matthew P. Young Ownership Network
Ownership Network List of Matthew P. Young
Ownership Network Relation of Matthew P. Young
Matthew P. Young Owned Company Details
What does CytomX Therapeutics Inc do?
Who are the key executives at CytomX Therapeutics Inc?
Matthew P. Young is the director of CytomX Therapeutics Inc. Other key executives at CytomX Therapeutics Inc include SVP & Chief Scientific Officer Marcia Belvin , SVP & Finance and Accounting Christopher Ogden , and Chief Medical Officer Yu-waye Chu .
CytomX Therapeutics Inc (CTMX) Insider Trades Summary
Over the past 18 months, Matthew P. Young made no insider transaction in CytomX Therapeutics Inc (CTMX). Other recent insider transactions involving CytomX Therapeutics Inc (CTMX) include a net sale of 85,328 shares made by Sean A. Mccarthy , a net sale of 40,565 shares made by Marcia Belvin , and a net sale of 23,729 shares made by Lloyd A Rowland .
In summary, during the past 3 months, insiders sold 79,947 shares of CytomX Therapeutics Inc (CTMX) in total and bought 0 shares, with a net sale of 79,947 shares. During the past 18 months, 183,963 shares of CytomX Therapeutics Inc (CTMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 183,963 shares.
CytomX Therapeutics Inc (CTMX)'s detailed insider trading history can be found in Insider Trading Tracker table.
CytomX Therapeutics Inc Insider Transactions
Matthew P. Young Mailing Address
Above is the net worth, insider trading, and ownership report for Matthew P. Young. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Matthew P. Young's mailing address is: Dublin L2 4 L2.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
